Feeds
Genentech and Biogen Idec Inc. said Friday the drug candidate Ocrelizumab met key goals in a late-stage rheumatoid arthritis study.
Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration is withholding a decision to expand approval of Rituxan as a leukemia treatment, pending further discussion.
Medicare officials are backing off a policy that pushed many doctors to use a $2,000 injectable drug for a potentially blinding eye disorder, over a similar treatment that costs about $50.
A Democratic senator says a shift in Medicare policy would encourage doctors to use an eye drug that costs thousands of dollars, over a similar treatment that costs just $50.
Biotech drugmaker Genentech Inc. said Sunday the Food and Drug Administration approved its cancer treatment Avastin for a new use against a form of kidney cancer, marking the sixth approval for the blockbuster drug.
Swiss drugmaker Roche plans to keep the chairman and chief executive of newly acquired biotech drug developer Genentech on board as chairman of the unit and named a Roche executive as its new CEO, the company said Tuesday.
The Genentech unit of drugmaker Roche Holding AG is pulling the psoriasis treatment Raptiva off the U.S. market because of links to an often fatal brain infection.
Preliminary studies of a blockbuster drug from Roche's Genentech unit are strong enough to speed up its approval for brain cancer, federal cancer experts said Tuesday.
Federal health regulators said Friday it's unclear whether Genentech's blockbuster cancer drug Avastin significantly shrinks the deadliest type of brain tumor.
Swiss pharmaceutical giant Roche agreed to pay $46.8 billion to buy the 44 percent of biotech pioneer Genentech that it doesn't already own, ending a long corporate struggle with its U.S.-based cancer drug partner.
Genentech's board of directors is close to striking a $95-per-share sale to cancer drug partner Roche, according to a report by the Wall Street Journal.
Swiss drug developer Roche boosted its hostile tender offer for biotechnology pioneer Genentech Inc. to $93 per share Friday, raising the total offer value to $45.7 billion, after its initial offer failed to pick up much support from shareholders.
Genentech Inc. on Monday touted its culture of innovative research and offered detailed long-term sales projections as it made its case to Wall Street on what it considers a low buyout bid from drugmaker Roche.
Genentech Inc. on Monday urged shareholders to reject a $42 billion hostile buyout bid from Swiss drugmaker Roche.
Swiss drugmaker Roche on Monday officially launched its $42 billion hostile offer for the 44 percent of Genentech Inc. it doesn't already own.
Roche's hostile bid for Genentech Inc., which became official late Monday, revealed just how far apart the companies are on valuing Genentech, with the biotechnology pioneer at one point asking for $112 per share, far more than Roche's initial bid.
Swiss drugmaker Roche Holding AG surprised Wall Street with plans for a lower-than-expected and hostile $42.1 billion buyout offer for Genentech Inc. Friday, a move some consider a tactic to force negotiations with the biotechnology behemoth.
Genentech Inc.'s fourth-quarter profit rose 47 percent on sales of its blockbuster cancer drug Avastin, but the biotechnology company set a weaker-than-expected outlook for 2009.
The Food and Drug Administration said Thursday it will update the labeling of Genentech Inc.'s psoriasis drug Raptiva to highlight the risk of several bacterial and viral conditions.
In an Oct. 14 story about Genentech's third-quarter results, The Associated Press erroneously reported financial forecasts by analysts surveyed by Thomson Reuters, wrongly indicating that Genentech had met expectations.
Genentech Inc.'s third-quarter profit rose 6.7 percent on rising sales of key cancer drugs, the biotechnology company said Tuesday, matching Wall Street's profit forecasts.
Federal regualtors said Thursday one case of a deadly brain infection has been reported in a patient taking Genentech and Biogen Idec's blockbuster arthritis and cancer drug Rituxan.
Biotechnology giant Genentech Inc. rejected a $43.7 billion buyout offer from its majority owner Roche on Wednesday but said it is open to a higher takeover bid.
Biotechnology pioneer Genentech Inc. mulled Roche Holding's $43.7 billion offer for its remaining shares Monday as investors made clear their feelings that the Swiss pharmaceutical giant should pay considerably more.
Swiss pharmaceutical maker Roche on Monday offered $43.7 billion for the remaining shares of its U.S. biotech partner Genentech Inc., seizing the opportunity offered by the weak U.S. dollar to grab a bigger share of earnings from such Genentech drugs as the blockbuster cancer treatment Avastin.
Also in that Room: Democratic Biotech-Paid Whores In my last post, I showed you what a roomful of Republican biotech-paid whores looks like. But in that same room are the following Democratic biotech-paid whores.
What a Roomful of Republican Biotech-Paid Whores Looks Like As the NYT reported earlier today, Genentech/Roche wrote a Republican script and a Democratic script for its parrots to enter into the Congressional Record.
Congressional Puppetry: Biotech Lobbyists Ghost-Write Health-Care Reform Speeches for 42 House Members22 Republicans and 20 Democrats -- who says bipartisanship is dead in Washington?
Federal Antitrust Probe Targets Tech GiantsThe Justice Department has launched an investigation into whether some of the nation's largest technology companies violated antitrust laws by negotiating the recruiting and hiring of one another's employees, according to two sources with knowledge of the review.
Empathy comes naturally to childrenWhen children see others in pain, their brains respond as if it were happening to them, U.S. researchers said on Friday.
F.D.A. Extends Avastin's Use to Breast CancerThe Food and Drug Administration approved Genentech's best-selling drug, Avastin, as a treatment for breast cancer, in a decision that appeared to lower the threshold somewhat for approval of certain cancer drugs.
Genentech wins US approval to use Avastin to treat breast cancerGenentech won U.S. approval to market its top-selling treatment Avastin for women with breast cancer, giving the company a chance to add more than $700 million in sales this year.
Genentech Debacle Highlights Larger Problems with Pharmaceutical ResearchAs the drug industry grapples with patent expirations and a chronic lack of exciting drugs in the pipeline, Levinson (Genentech CEO) faces a unique challenge—living up to his own track record.
FDA Panel Votes Against New Avastin UseWASHINGTON -- A panel of government experts said Wednesday that Genentech's cancer drug should not be approved for expanded use in breast-cancer patients.
NHS doctors challenge high drugs pricesBritish doctors are to rebel against high prices set by pharmaceutical companies for their products by giving patients a cheap but unlicensed drug that prevents blindness, the Guardian has learned.
Lawmakers Offer U.S. Plan for Generic Biotech DrugsMakers of generic drugs would gain the right to sell copies of medicines developed by biotech companies such as Amgen Inc. and Genentech Inc. under legislation to be introduced in the U.S. Senate.
An ASCO Round-Up For YouAdding ImClone's Erbitux to a regimen of chemotherapy prolonged survival more than chemotherapy alone in patients with head and neck cancer that has recurred or spread, according to a study.
Genentech Data on Cancer Drug Avastin Potentially Revenue DamagingCHICAGO -- The annual meeting of the American Society of Clinical Oncology has traditionally been the forum where Genentech and its blockbuster cancer drug Avastin run away with best-in-show honors.
Google takes biotech stakeGOOGLE has notified the market that it has taken a small stake in a biotech company that was co-founded by the wife of one of Google's founders, Sergey Brin,
Study shows Drug Reps Sway Doctors' Choices As much as doctors would like to deny it, subtle attention from friendly drug sales representatives can have a big impact on what drugs they prescribe, according to two U.S. studies published on Monday.
Another blow for big pharma?Medical and biotechnology IP battles, while less visible than the name-calling campaigns of electronic companies, remain as fierce as ever.
The Biotech Industry: 30 Years of Failure!Harvard business professor Gary P. Pisano provides eye opening proof showcasing how the biotech industry has failed in its attempt to function as a science-based business.
Guardian Unlimited | Special reports | Drugs firm blocks cheap blindness cureEven though I've come to expect Pharmaceutical companies to overprice their products this seems a little excessive.
Log In | Register
